Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials

BACKGROUND: Two randomized controlled trials (reSURFACE 1 and 2) have demonstrated the effectiveness of tildrakizumab, a high‐affinity, humanized, IgG1κ, anti‐interleukin‐23 monoclonal antibody, for treating moderate‐to‐severe plaque psoriasis in the first 28 weeks. OBJECTIVES: To examine the effica...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Eur Acad Dermatol Venereol
Main Authors: Blauvelt, A., Sofen, H., Papp, K., Gooderham, M., Tyring, S., Zhao, Y., Lowry, S., Mendelsohn, A., Parno, J., Reich, K.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Psoriasis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6899626/
https://ncbi.nlm.nih.gov/pubmed/31407394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.15862
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados